CRIS News

Curis to Present at Upcoming Healthcare Conferences in September

(NASDAQ:CRIS) LEXINGTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis,...

September 2, 2025Conferences

HC Wainwright & Co. Assumes Curis at Buy, Announces Price Target of $17

CRIS

May 19, 2025

Curis Q1 EPS $(1.25) Misses $(0.87) Estimate, Sales $2.38M Miss $2.75M Estimate

CRIS

May 6, 2025

Earnings Outlook For Curis

CRIS

May 5, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

CRIS

April 2, 2025

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $16

CRIS

March 31, 2025

Curis Says Orphan Drug Designation For PCNSL Granted In U.S. And EU

CRIS

March 31, 2025

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $20 Price Target

CRIS

November 15, 2024

Curis Q3 2024 GAAP EPS $(1.70) Beats $(1.83) Estimate, Cash And Cash Equivalents Of $31.6M Is Expected To Provide Cash Runway Into Mid-2025

CRIS

November 14, 2024

Curis 13G Filing Shows Thomas A. Satterfield, Jr. Reported A 8.05% Stake In The Co As Of October 30, 2024

CRIS

November 1, 2024

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $20

CRIS

November 1, 2024

Earnings Outlook For Curis

CRIS

Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an earnings per share (EPS) of $-0.16.

May 4, 2022